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Background and Objective. To compare the efficacy
of ProME(Epidoxorubicin)CE-CytaBOM (PE-C) and
ProMI(Idarubicin)CE-CytaBOM (PI-C) in the treatment
of adult patients with aggressive non Hodgkin’s lym-
phoma in a multicenter randomized controlled trial
performed by 18 centers of the Italian Lymphoma
Study Group (GISL).
Design and Methods. One hundred and twenty-eight
and 122 patients were randomly assigned to receive
either 6 courses of PE-C or PI-C, respectively. Some
patients achieving complete remission with induction
therapy participated in another randomized study
comparing no further therapy versus maintenance
therapy consisting of four blocks of two drugs.
Results. The rate of CRs was 62% and 64% for
patients treated with PE-C and PI-C, respectively
(p=0.51). The 5-year relapse-free survival was 60%
for PE-C and 53% for PI-C (p=0.29). The estimated
relapse-free disease survival rates at 4 years were
75% for patients in the consolidation group and 57%
for those in the observation group (p=0.11). Patients
alive in first complete remission 4 years after study
entry were estimated to be 39% in the PE-C arm and
38% in the PI-C arm (p=0.90). The 3-year and 5-year
estimated survival rates were 61% and 55% for the
PE-C group and 56% and 47% for the PI-C group
(p=0.26). Fatal toxicities occurred in 7 patients
(2.9%) with active disease and in 4 patients (1.7%)
in complete remission. Stage (p=0.04),  bulky dis-
ease (p=0.02), serum LDH (p=0.0006), serum albu-
min (p=0.0051), hemoglobin (p=0.0011), perfor-
mance status (p=0.0001), International prognostic
index (p<0.0001) and the index proposed by the
French group G.E.L.A. (p<0.0001) were of prognostic
value. In a multivariate analysis (Cox regression mod-
el) alternatively IPI alone or G.E.L.A. index plus per-
formance status emerged as independent prognostic
factors.
Interpretation and Conclusions. The present study
indicates that epirubicin and idarubicin in a combined
chemotherapy regimen, have similar activities. The
toxic profile also indicates the safety of both anthra-
cyclines at the dosages employed, suggesting their
possible dose escalation in a combined chemothera-
py setting. PE-C and PI-C were both effective and fea-
sible regimens in an outpatient setting, with accept-
able cardiovascular toxicity. The trend toward a bet-
ter outcome in patients undergoing consolidation
therapy after the achievement of a complete remis-
sion, warrants further investigation.
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Twenty years on from the introduction of thecyclophosphamide, doxorubicin, vincristine,and prednisone (CHOP) regimen, the optimal
therapy of aggressive non-Hodgkin's lymphomas
(NHL) is still a matter of debate.1,2 Although no doubt
exists that different doxorubicin-based regimens are
effective therapies for patients with aggressive NHL,3-
8 the magnitude of the benefit of the so called second
and third generation regimens over CHOP seems
questionable.9-14 In fact, although some prospective
randomized trials have shown no advantage of sec-
ond or third generation regimens over CHOP,9-12 oth-
er groups have found a significant benefit with dose
intensification, including the EORTC study compar-
ing CHVmP vs CHVmP plus vincristine and
bleomycin13 and the Italian NCI study performed by
Gianni et al., comparing MACOP-B to more intensive
therapy.14
In the mid ’80s several pilot studies produced very
promising results, suggesting that the majority of
patients with advanced, diffuse, aggressive NHL could
be cured. The combination of methotrexate, bleo-
mycin, doxorubicin, cyclophosphamide, vincristine,
and dexamethasone (m-BACOD);3 methotrexate, dox-
orubicin, cyclophosphamide, vincristine, prednisone,
and bleomycin (MACOP-B);4 cyclophosphamide, dox-
orubicin, etoposide, prednisone, bleomycin, cytara-
bine, and methotrexate (ProMACE-CytaBOM);5 dox-
orubicin, cyclophosphamide, vindesine, bleomycin,
prednisolone, and intrathecal methotrexate (ACVB)6
all determined CR rates of over 80%, allowing the
notion that significant progress in the cure of NHL had
been achieved. However, these very promising results
were not confirmed by large phase III randomized stud-
ies,9-12,16,17 confirming that multicenter trials yield less
favorable results in the attempt to reproduce the best
results published in the literature. When ProMACE-
CytaBOM was used in a multicenter trial by SWOG,
the CR rate decreased to 65%.18 In the period 1988-
1990 our cooperative group undertook a randomized
study comparing MACOP-B and ProMACE-CytaBOM
in patients with intermediate and high grade NHL. The
final results of this experience showed that no more
than 63% of patients achieved a CR, with MACOP-B
and ProMACE-CytaBOM being similarly effective.15
In 1991, in an effort to improve the results of treat-
ment of aggressive NHL, we designed the prospective
study LA02, based on induction therapy with Pro-
MACE-CytaBOM. The aims of the study were: 1) the
comparison of two different anthracyclines substituting
adriamycin in ProMACE-CytaBOM; 2) to assess the
usefulness of a short maintenance treatment for
patients achieving complete remission; 3) to evaluate
the efficacy of early salvage therapy for patients not
responding after three courses of ProMACE-CytaBOM.
Following two preliminary reports containing the
results of a formal interim analysis,19,20 we now report
the final results of this trial, closed in June 1993, when
the planned 250 patients had been accrued.
Materials and Methods
Between April 1991 and June 1993, 250 patients
with NHL were registered for the study and random-
ized to receive combination chemotherapy with either
ProME(Epidoxorubicin)CE-CytaBOM (PE-C) or Pro-
MI(Idarubicin)CE-Cytabom (PI-C). Criteria for inclu-
sion in the study were histologic diagnosis of inter-
mediate-grade (IG) or high-grade (HG) NHL other
than lymphoblastic lymphoma (i.e. categories D-H
and K of Working Formulation);  no prior treatment;
clinical stage II, III, and IV, or clinical stage I with
bulky disease; age over 12 years. Patients over 70
years of age were also included on the basis of good
performance status and in the absence of underlying
coronary artery or pulmonary disease.
All patients were clinically staged according to the
Ann Arbor system. Patients with acquired immune
deficiency syndrome (AIDS), AIDS-related complex
(ARC), or positive serology for HIV were not eligible
for this study and were assigned to a different treat-
ment program. 
Treatment protocol
Patients were randomly assigned to receive either 6
courses of PE-C or PI-C and were stratified on the basis
of stage (II-III or IV) and participating center. The two
ProMACE-CytaBOM derived regimens were given
according to the schedule proposed by Fisher et al.5
Briefly, chemotherapy was administered as follows:
cyclophosphamide 650 mg/m2 intravenously (IV),
etoposide 120 mg/m2 IV, epidoxorubicin 30 mg/m2
IV (or idarubicin 6 mg/m2 IV) all on day 1, prednisone
60 mg/m2 orally on days 1-14, and cytarabine 300
mg/m2 IV, bleomycin 5 mg/m2 IV, vincristine 1.4
mg/m2 IV (cap = 2 mg), methotrexate 120 mg/m2 IV
on day 8 with leucovorin 10 mg/m2 orally for 5 doses
beginning 24 hours after methotrexate administration.
Epidoxorubicin was chosen on the basis of its lower
cardiac toxicity but same tumor effectiveness.21 Idaru-
bicin was chosen because it has shown promising
results in most lymphoproliferative disorders, includ-
ing acute leukemias and relapsed or refractory malig-
nant lymphomas.22
Cycles were repeated every three weeks. After three
cycles of therapy, patients achieving complete or par-
tial remission continued to receive 3 additional cours-
es, whereas non responding patients were shifted to
different salvage treatments. At the end of the 6
planned courses of therapy, patients could receive
additional radiotherapy on residual masses or on sites
of previously bulky disease. Finally, patients achieving
complete remission with induction therapy were invit-
ed to participate in a randomized study comparing no
further therapy versus a consolidation regimen con-
sisting of four blocks of two drugs, according to the
following schedule: thioguanine 300 mg/m2 on days
1-4 and cyclophosphamide 600 mg/m2 on day 5;
hydroxyurea 2400 mg/m2 on days 1-4 and epidox-
orubicin 50 mg/m2 on day 5; methotrexate 10 mg/m2
on days 1-4 and carmustine 60 mg/m2 on day 5; cyta-
rabine 150 mg/m2 on days 1-4 and vincristine 1.5
mg/m2 on day 5. Each block was administered every
two weeks; after the fourth block the sequence was
repeated once, starting from block 1. Dosage modifi-
cations were made according to WBC and platelet
counts on the day of scheduled treatment. 
All patients received prophylactic cotrimoxazole
and ketoconazole or fluconazole daily throughout
the treatment program. Antiemetic prophylaxis con-
sisted primarily in almost all cases of 50 mg promet-
hazine, i.m., 45 minutes before chemotherapy, and
0.5 mg/kg metoclopramide or levosulpiride i.v.
immediately before chemotherapy. 
Assessment of response
Response to treatment was assessed one month
after the end of induction therapy by performing all
examinations necessary to check abnormal findings
present at the time of entry to the study. Complete
remission (CR) was defined as the disappearance of all
clinical evidence of disease and the normalization of
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all laboratory values and radiographs that had been
considered abnormal before starting treatment.
Patients with stable residual masses lasting 6 months
were retrospectively classified as CR. Moreover,
patients who achieved a CR during therapy, but who
relapsed within 30 days of therapy having been com-
pleted, were classified as non responders. Partial
remission (PR) was defined as a greater than 50%
reduction in the largest dimension of each anatomic
site of measurable disease for at least one month. No
remission (NR) was defined as a less than 50% regres-
sion or stable or progressive disease. All early deaths
due to disease progression or treatment-related toxi-
city were considered as treatment failure, and includ-
ed in the group of NRs. Toxicity was assessed accord-
ing to the WHO criteria.
Statistical analysis
All data were analyzed with the Statistical Package
for the Social Sciences (SPSS).23 Differences in CR
rates, number and severity of therapy related side
effects, and causes of death between the two groups
were analyzed by Fisher's exact test for contingency
tables. Grades were grouped when there were too few
patients with higher grades. Survival, disease free sur-
vival (DFS), and time to treatment failure (TTF) curves
were estimated by the Kaplan-Meier method. The log-
rank test was used to assess the significance of differ-
ences in survival, DFS, or TTF for each prognostic fac-
tor. Survival was calculated from the beginning of
treatment until death from any cause. DFS was cal-
culated from the end of induction therapy to the first
evidence of disease relapse. TTF was measured from
the beginning of therapy to the time of disease pro-
gression, relapse, or death. Response rates, TTF, sur-
vival, and toxicity were analyzed among the patients
who were eligible and could be evaluated. Differences
in survival according to treatment group were studied
between randomized patients in an intention-to-treat
analysis. Cox proportional hazards regression model-
ing was used in multivariate analysis to determine
whether the identified risk factors independently influ-
enced survival rates. The relevance of the internation-
al NHL prognostic factors project index24 (IPI), and of
the prognostic index proposed by the French Group
G.E.L.A.25 was also evaluated. The clinical usefulness
of the prognostic index proposed at the M.D. Ander-
son Cancer Center26 was not tested because the val-
ue of b2-microglobulin was lacking for the majority of
cases. For the assessment of the IPI we had to convert
the value of performance status in our patients from
the Karnofsky to the ECOG scale. We considered the
presence of a Karnofsky performance status of 0 to 70
to be an adverse prognostic factor. A p value of 0.05
(two-sided) was considered the limit of significance
for all the analyses.
Dose intensity
The dose intensity (DI) analysis was performed
according to the method proposed by Hryniuk.27 For
patients completing the planned 6 courses of
chemotherapy the DI of each drug was considered the
amount of each drug, normalized to the body surface
area, administered during the first 119 days, 119 days
being the time necessary to deliver 6 courses of thera-
py one every 3 weeks. The time necessary to complete
the sixth course was considered to be 14 days. For
patients who received less than 6 courses of
chemotherapy because of early death or disease pro-
gression, DI was expressed as the ratio of the dose
actually delivered to the dose prescribed in the regimen
over the same time frame. 
Results
One patient out of the 250 enrolled was subse-
quently considered ineligible when the histology was
reviewed. The remaining 249 patients, 128 in the PE-
C arm and 121 in the PI-C arm, were included in the
analysis. Table 1 summarizes the characteristics of
these patients, divided according to the two treatment
arms. No statistical differences between study arms
were observed as regards the baseline characteristics.
Response
Eight patients were withdrawn from the study before
the first assessment of response, planned after three
courses. Reasons for early withdrawn were: refusal to
receive planned therapy (n = 3); major toxicity after the
first course (n = 4, one fatal); death due to cerebral
hemorrhage after the first course (n = 1). The remain-
ing 241 patients (125 in the PE-C and 116 in the PI-C
arm) were assessable for response (Table 2).
After three courses of therapy, 46 patients (37%)
treated with PE-C and 46 (39%) treated with PI-C
achieved a CR, with no significant difference between
the two treatment arms (p=0.27). Moreover, 60
patients (48%) treated with PE-C and 58 (50%) treat-
ed with PI-C achieved a PR. The objective response
(CR+PR) rate for the whole group was 87%. Thirty-
one patients were classified has having stable or pro-
gressive disease. Sixteen deaths were recorded among
these non responding patients (13 for disease pro-
gression, 2 due to toxicity and 1 from sudden death)
within the 3 months following study entry. Fourteen
patients with stable or progressive disease left the
study and were subsequently shifted to salvage ther-
apy; only one patient achieved a CR with second line
therapy. Finally, regardless of an unsatisfactory initial
response, one patient continued with initial therapy
on judgment of the physician, obtaining a minimal
response at the end of 6 courses. This patient subse-
quently obtained a CR, lasting 3 years, with high-
dose therapy followed by stem cell support.
After six cycles, 71 patients (57%) treated with PE-
C and 73 (63%) treated with PI-C achieved a CR, and
again the differences between the two treatment arms
were not significant (P=0.36). Eight patients in PR
after chemotherapy achieved a CR with additional
IF-RT. In conclusion 152 patients (63%) achieved a
CR with induction therapy. The rate of CRs was 62%
M. Federico et al.802
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and 64% for patients treated with PE-C and PI-C
respectively, with no significant differences between
the two groups (P=0.51).  Sixty-one relapses (40%)
occurred among 152 patients achieving CR. The rate
of relapses was similar in the two groups, 29/77
(38%) in the PE-C arm and 31/75 (43%) in the PI-C
arm (P=0.33). The 5-year relapse-free survival was
60% in PE-C group and 53% in PI-C group (Figure 1).
The differences in relapse-free survival were not sig-
nificant (P=0.29). A second complete remission was
obtained with salvage therapy in 17 patients (28%).
Failures
At the time of the present analysis we recorded 160
treatment failures, including resistance to initial ther-
apy, relapses, or death from any cause. We observed
82/125 failures (66%) in the group treated with PE-
C and 78/116 failures (67%) among those treated
with PI-C (p=0.78). The percentages of patients alive
in first complete remission 4 years after study entry
were estimated to be 39% in the PE-C arm and 38%
in the PI-C arm (Figure 2); the difference between the
groups was not significant (p=0.90). When the 10
patients who failed to achieve a CR with initial ther-
apy but obtained a CR with second line therapy, and
17 patients who relapsed and achieved a second CR
were also considered, the percentage of patients alive
without disease at four years was estimated to be
53% and 49% in the PE and PI groups respectively.
The differences between the two groups were not sig-
nificant (p=0.46).
Consolidation
Forty-two patients achieving CR with induction ther-
apy were randomly assigned to consolidation therapy
or observation only. The remaining 110 patients in CR
were not randomized for different reasons, including
refusal from the patient or lack of compliance from the
physician. Twenty-one patients, 10 in the PE-C and
11 in the PI-C arm, were randomized to consolidation
therapy and 21 to observation only. After a median
follow-up of 35 months, 4 relapses (19%) were
observed among treated patients and 9 relapses (43%)
among patients in the observation arm, suggesting a
better, although not statistically significant (p=0.10)
outcome for patients undergoing a maintenance pro-
gram. Interestingly, the rate of relapse of patients in
the observation arm was similar to the rate of relapse
(48 patients, 44%) observed in the group of 110
patients who were not enrolled in this part of the tri-
al. The estimated relapse-free disease survival rates at
4 years were 75% for patients randomized to mainte-
nance, 57% for patients randomized to observation
and 53% for those not randomized (p=0.15 consider-
ing all 3 groups, 0.11 considering only the study arms)
(Figure 3).
Survival
After a median follow-up of 34 months (53 months
for patients alive), 118 patients (47%) had died, 7
had been lost from follow-up (3%) and 124 were
alive; there were 56 deaths (44%) among 129
patients assigned to the PE-C arm and 60 (49%)
among the 121 patients assigned to the PI-C arm.
The causes of death are summarized in Table 3. No
significant difference in death-rate was found
between the two treatment arms (p=0.28). One
patient in each group died in a car accident, while in
CR. These two patients were censored at the time of
death. As expected, the majority of deaths (n = 103)
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Figure 1: Relapse-free survival according to treatment group for the 152 patients who achieved complete remission with induc-
tion therapy. (—) PE-C, 77 cases; (- - - -) PI-C, 75 cases (Log rank test = 1.12, p = 0.29).
Months after achievement of complete remission
occurred in patients with active disease. However 13
deaths occurred in patients in complete remission
after a median time of 18 months from study entry.
Two cases of acute hepatitis and one of CMV infec-
tion occurred in patients who had successfully com-
pleted the planned induction therapy. Finally, one
patient in CR after induction therapy underwent
autologous bone marrow transplantation (ABMT)
and died of ABMT-related toxicity. Fifty-one percent
of the 249 patients were estimated to be alive at 5
years. The 3-year and 5-year estimated survival rates
were respectively 61% and 55% for the PE-C group and
56% and 47% for the PI-C group (Figure 4). The dif-
ference was not significant (p=0.26).
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Figure 3.  Relapse-free survival of patients who achieved complete remission and were randomized to maintenance therapy or
to observation. (—) Maintenance arm: 21 patients at risk, 4 relapses; (- - - -) observation arm: 21 patients at risk, 9 failures.
(Log rank test = 2.51, P=0.11).
Figure 2. Failure-free survival according to treatment group. (—) PE-C: 125 patients at risk, 82 failures; (- - - -) PI-C:, 116 patients
at risk, 78 failures. (Log rank test = 0.02, p=0.90).
Months after achievement of complete remission
Months after randomization
Cardiovascular toxicity
The hematologic and non hematologic toxicity was
acceptable in both arms as previously reported.20
The incidence, distribution and severity of cardio-
vascular toxicity was similar in the two groups (Table
4). Five patients treated with PE-C and 7 treated with
PI-C experienced a cardiovascular adverse event. All
4 patients who died of cardiovascular toxicity had
active disease at the time of death. The remaining 8
patients experiencing cardiac abnormalities recov-
ered completely with appropriate treatment. 
Analysis of prognostic factors
Advanced stage (p=0.04), presence of bulky disease
(p=0.02), serum LDH above the upper normal limit
(p=0.0006), low serum albumin (p=0.0051) low
hemoglobin (p=0.0011) and low performance status
(p=0.0001) were associated with a poorer prognosis
in a univariate analysis of survival (Table 5). More-
over, the international prognostic index (IPI) and the
prognostic index adopted by the French group
G.E.L.A. both provided highly significant prognostic
value. Using IPI the 5-year survival rate was 61% in the
group at low risk, 56% in the group at intermediate-
low risk, 41% in the group at high-intermediate risk,
and 22% in the group at high risk (p < 0.0001). Using
the G.E.L.A. index, the 5-year survival was 75% in the
group at low risk, 55% in the group at intermediate risk
and 36% in the group at high risk (p < 0.0001). Dose
intensity was not found to be a prognostic factor for
patients accrued in the present trial. However, only a
minority of patients received less than the planned
dose. Several cut-off levels of DI (0.70, 0.75, 0.80,
0.90) were explored, but no differences emerged as
regards to overall survival, DFS or TTF (data not
shown). 
In a multivariate analysis of those prognostic fac-
tors of statistical significance in univariate analysis of
survival performed using the Cox regression model,
no independent factors emerged, probably because
most of the variables reflect similar biological phe-
nomena. However excluding from the model those
variables already considered by IPI (i.e. stage, LDH,
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Table 3. Causes of death, according to treatment group°.
Cause ProMECE-CytaBOM ProMICE-CytaBOM
no. of deaths
Active disease
Disease progression 42 48
Neutropenia and/or sepsis 6 2
Acute myocardial infarction 1 1
Cerebrovascular accident 0 2
Hemorrhagic shock 0 1
49 54
Complete remission
Neutropenia and/or sepsis 2 3
Acute hepatitis 1 1
CMV infection 1 0
ABMT-related toxicity 1 0
Second neoplasm 2 1
Unknown 0 1
7 6
Total 56 60
°Excluding one patient per arm who died due to a car accident.
Figure 4. Overall survival by treatment group, according to intent-to-treat analysis. (—) PE-C: 128 patients at risk, 56 deaths;
(- - - -) PI-C:, 121 patients at risk, 60 deaths. (Log rank test = 1.29, p = 0.28).
Months after randomization
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and PS) the latter resulted of independent value, but
no additional factor was able to improve the prog-
nostic power of the model. In contrast a multivariate
analysis considering hemoglobin, serum albumin, PS
and G.E.L.A. index revealed an independent  prog-
nostic value of G.E.L.A. and PS.
As expected, a highly significant correlation was
found between the IPI and G.E.L.A. index (p < 0.0001)
although complete agreement in the assessment of
the risk was observed in only 57% of cases, as shown
in Table 6. In the group of patients aged 60 or less,
and more likely to be suitable for more aggressive
treatments, including high-dose therapy followed by
stem cell support, 28 were at intermediate-high or
high risk according to IPI, and 56 resulted at high risk
according to the G.E.L.A. index. Twenty-five patients
were at high risk according to both prognostic mod-
els, 3 according to the IPI but not to the G.E.L.A.
index, and 31 according to the G.E.L.A. index but not
to the IPI.
Dose intensity
Data for calculation of dose intensity were avail-
able in 217 patients (115 treated with PE and 102
treated with PI). Patients received 81% of the planned
dose of vincristine, and 93%, 94%, 94%, 96%, 97%,
97%, and 100% of the planned doses of idarubicin,
methotrexate, epidoxorubicin, cytarabine, cyclophos-
phamide, etoposide, and bleomycin,  respectively.
The average DI of vincristine was low because almost
all patients had body surface areas >1.43 m2 and were
thus able to receive the upper limit of 2 mg. Howev-
er, in most cases some delay in the delivery of thera-
py occurred. The mean duration of the six cycles was
23, 24, 27, 25, 25, and 22 days, respectively. The
higher mean duration of the third course was in part
dependent on the necessity of performing the re-stag-
ing procedures planned after three courses of
chemotherapy. Considering both the dose of drugs
delivered and the time necessary for completing the
planned therapy, the actual DI was equal to 92% in
the whole group. The actual DI was 92% in the group
treated with PE-C and 91% in the group treated with
PI-C (p=0.67). Several cut-off levels of DI (0.70, 0.75,
0.80, 0.90) were explored, but no differences emerged
as regards to overall survival, DFS or TTF.
Discussion
The principal end-point of the LA02 protocol was
the demonstration that PI-C had equivalent efficacy
to PE-C with an improved toxicity profile, and the tri-
al showed that there were no differences in the rate of
complete remission, failure-free survival, relapse-free
survival and overall survival between the two study
groups, well balanced with respect to prognostic fac-
tors. In agreement with other reports, the present
study also indicates that epirubicin and idarubicin in
a combination chemotherapy regimen have similar
activities. In a randomized trial comparing VACOP-B
versus VICOP-B, Bertini et al. found that both regi-
mens had the same efficacy in the treatment of
patients with diffuse large cell lymphoma.30
Similarly, Zinzani et al. tested the efficacy of idaru-
bicin instead of doxorubicin in the CHOP regimen,
and found that the idarubicin arm had an equivalent
therapeutic efficacy in comparison to the standard
doxorubicin containing CHOP.31 Cardiovascular tox-
icity was also comparable, although in this case the
lack of difference is possibly due to the limited num-
ber of cardiovascular events recorded in both study
arms. However, this toxic profile indicates the safety
of both anthracyclines at the dosages employed, sug-
gesting their possible dose-escalation in a combina-
tion chemotherapy setting.
Several Institutions or Cooperative groups have
adopted ProMACE-CytaBOM as first line therapy of
patients with aggressive NHL.5,9,15,18,32,35 In a random-
ized trial conducted at NCI comparing ProMACE-
CytaBOM with ProMACE-MOPP in more than 200
patients, Longo et al. reported that ProMACE-
CytaBOM was highly effective, with a complete
response rate of 86%, and an estimated overall survival
rate at 6 years of 69%.28 However this was a trial con-
ducted in a single institute and, like most trials of this
type, some selection bias could have favored these
excellent results. Although we were not able to repli-
cate the very promising results obtained at NCI, our
results are consistent with those obtained by other
multicenter trials. In the large SWOG-ECOG trial com-
paring CHOP with m-BACOD, MACOP-B and Pro-
MACE-CytaBOM the complete remission rate
achieved with ProMACE-CytaBOM was 56%.9 In the
SWOG study reported by Miller et al., a CR was
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Table 7. Comparative studies with regards to the percent-
age of patients considered elegible after enrolment.
Study Group Regimen No. No. Rate of
enrolled eligible eligible (%)
Fisher et al.9 CHOP 1138 899 79
m-BACOD
ProMACE-CytaBOM
MACOP-B
Gordon et al.10 CHOP 392 325 83
m-BACOD
Cooper et al.11 CHOP
MACOP-B 304 236 78
Montserrat et al.12 CHOP
ProMACE-CytaBOM 175 148 85
Meerwaldt et al.13 CHVmP
CHVmP/OB 430 346 80
Bezwoda et al.34 CHOP
CNOP 325 263 81
Meyer et al.40 BACOP
ESCALATED BACOP 298 236 79
Present study ProMACE-CytaBOM
ProMICE-CytaBOM 250 249 99
 
obtained in 65% of 78 previously untreated patients.18
Other investigators reported CR rates ranging from 62
to 70%.12,29,32 In our opinion the complete remission
rate of 62% and 64% achieved with PE-C and PI-C are
of value, mostly considering that LA02 is a multicen-
ter randomized study performed in 18 institutions and
that response rate was calculated on nearly all ran-
domized patients. After study entry no patient was
excluded from the analysis for lack of complete agree-
ment with inclusion criteria (i.e. low performance sta-
tus, concomitant diseases, advanced age and so on).
Thus in the present study 96% of patients were includ-
ed in the calculation of response and 99% in the analy-
sis of survival, while in other trials the percentage of
cases excluded from the analysis after study entry is rel-
evant, sometimes exceeding 20% of enrolled patients.9-
13,33,34,40 A comparison between our trial and these oth-
er studies is summarized in Table 7. Our evaluation
policy, which includes as many patients as possible
after study entry, is meant to offer a more realistic
measure of the efficacy of regimens under study. The
effect on the response rate of the exclusion of a sig-
nificant number of enrolled patients was  clearly high-
lighted by Bezwoda et al. in a study comparing CHOP
with CNOP chemotherapy in patients with intermedi-
ate and high-grade NHL: in that study the CR rate was
5% higher if the analysis was performed on eligible
instead of on all randomized patients.34
Since 1987 our group has treated more than 800
adult patients with NHL with ProMACE-CytaBOM-
derived schedules. Following a pilot study performed
in 1987 on 35 patients with aggressive NHL, between
1988 and 1991 we completed a randomized trial
comparing ProMECE-CytaBOM with MACOP-B. In
that trial 106 patients were treated with PE-C, and
62% achieved a CR.15 In addition to the 250 patients
enrolled in the present trial, we have used PE-C in 35
patients aged less than 55 years and affected by
advanced follicular NHL35 obtaining CR in 55% and
a 5-year disease free survival of 60%; in patients with
anaplastic large cell lymphoma36 we recorded a com-
plete remission rate of 62% in the PE-C group with an
estimated survival rate at 4 years of 54%. Moreover,
we currently treat patients with localized aggressive
NHL  with 4 courses of PE-C followed by IF-RT. Final-
ly, our on-going LA03 trial comparing a fixed versus a
flexible schedule of PE-C or PI-C has already enrolled
more than 330 patients. One of the most convincing
reasons for continuing to treat patients with Pro-
MACE-CytaBOM despite the fact that the National
High Priority Lymphoma Study comparing CHOP
with m-BACOD, ProMACE-CytaBOM, and MACOP-
B concluded that “CHOP remains the best available treat-
ment for patients with advanced-stage intermediate-grade or
high-grade NHL”,9 is that when physicians become
familiar with intensive regimens, protocols like Pro-
MACE-CytaBOM should yield better results than
CHOP, as suggested by Longo and Duffey.37
An additional goal of our trial was the demonstra-
tion that a short maintenance treatment for patients
achieving complete remission could ameliorate the
RFD survival. In the group of 42 patients who were
randomized, the 4-year RFS rate was 75% in the
maintenance and 57% in the observation arm, sug-
gesting a better outcome for patients continuing with
a maintenance program, although the difference was
not statistically significant (p=0.11). Unfortunately
since only a minority (28%) of patients in complete
remission after induction therapy was enrolled in this
part of the study, a definite answer on the role of a
maintenance therapy deserves further investigations. 
With this trial we also wanted to verify whether ear-
ly salvage therapy could be of benefit to patients not
responding after 3 courses of PE-C or PI-C. From the
present experience we noted that the majority of ini-
tially non responding cases died before receiving sal-
vage treatment and that the response to an early sec-
ond-line therapy was very poor. In fact, only one of
14 patients shifted to salvage therapy achieved a CR
with a salvage regimen. These results indirectly indi-
cate the great importance of prognostic stratification
at the onset of disease, with immediate therapy inten-
sification in high risk cases rather than an early
change of treatment to rescue cases with poor
response after the first courses.
In an attempt to improve the rate of cure of aggres-
sive NHL many investigators have explored the use-
fulness of a policy of DI intensification. Dose inten-
sity  is considered a major determinant of outcome,
and correlations between DI and survival have been
reported in retrospective analyses.38-41 Although it
would seem obvious that DI is an important deter-
minant of treatment outcome, the results of the very
few prospective trials are controversial. Based on
available data, it remains unclear what impact DI has
on treatment outcome. The Clinical Trials Group of the
National Cancer Institute of Canada recently reported the
results of a randomized trial comparing standard
BACOP with BACOP that included escalated doses
of doxorubicin. The complete remissions were 59%
and 61% respectively, with no significant differences
between the two groups.40 In a phase I trial of dose
escalation with growth factor support performed by
ECOG, the CR rate in the group of patients treated
with a dose equal to 200% of standard ProMACE-
CytaBOM was 66%,42 not dissimilar to the success
rate expected using standard doses. However, very
promising results were achieved by Shipp et al. using
high-dose CHOP,43 by Tanosaki et al. using bi-week-
ly CHOP,44 and by Bergmann et al. using VACPE, an
intensified chemotherapy regimen consisting of vin-
cristine, doxorubicin, cyclophosphamide, prednisone
and etoposide.45
Dose intensity was not found to have a prognostic
impact on patients included in the present trial. This
apparent lack of relevance of DI probably depends on
the fact that the actual DI was 92%, indicating good
dose delivery. Moreover, only a few patients com-
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pleted the planned therapy at DI lower than 80%.
In our study factors of prognostic value were stage
of disease, bulky disease, serum LDH, serum albu-
min, hemoglobin, performance status, IPI, and the
prognostic index adopted by the French group
G.E.L.A. In a multivariate analysis performed using
the Cox regression model IPI alone or PS and G.E.L.A.
index had independent  prognostic values. As expect-
ed, a highly significant correlation was found between
IPI and G.E.L.A. index although complete agreement
in the assessment of the risk was observed only in
57% of cases. In the group of patients aged 60 or
less, and probably suitable for more aggressive treat-
ments, 25 patients were at high risk according to
both prognostic models, 3 according to IPI but not
to the G.E.L.A. index, and 31 according to G.E.L.A.
alone. This comparison was performed in view of the
adoption of a prognostic index for selecting patients
who would be more likely to benefit from high-dose
therapy followed by stem cell support.14,46
In conclusion, our study has demonstrated that
standard dose regimens such as PE-C and PI-C are
effective therapies for patients with aggressive NHL at
low or intermediate risk.
Different approaches, including high-dose therapy
should be offered to patients at high risk, although it
should be taken into account that the definitions of
this risk category are widely heterogeneous and are
influenced by the adopted index. For example, the
use of the prognostic index proposed by G.E.L.A.
results in a 40% higher proportion of patients being
defined at high-risk than as by IPI.
Contributions and Acknowledgments
The authors wish to thank the GISL trial office for data col-
lection and preparation, the data managers at all participat-
ing institutions, Maristella del Grande and Tunde Dolan for
manuscript preparation.
MF, LB, MB, PG were responsible for the conception of the
study and its design; MF was also responsible for interpreta-
tion of data and writing of the paper; VC was responsible for
randomization, data handling and for drafting the paper with
MF; PG collaborated in reviewing the manuscript; DV, DD,
ML, PA, NDR were responsible for patient care and reviewed
the manuscript; VS gave the final approvation.
Funding
Supported in part by Grants from MURST (60%), Asso-
ciazione Italiana per la Ricerca sul Cancro (AIRC), Fon-
dazione Ferrata Storti and Associazione Angela Serra per la
ricerca sul cancro.
Disclosures
Conflict of interest: none.
Rendundant  publications: no substantial overlapping with
previous papers.
Manuscript processing
Manuscript received February 26, 1998; accepted June
10, 1998.
References
1. De Vita VT Jr, Hubbard SM, Longo DL. The chemo-
therapy of lymphoma: looking back, moving   forward.
Cancer Res 1987; 47:5810-24.
2. Armitage JO. Treatment of non-Hodgkin's lym-
phomas. New Engl J Med 1993; 328:1023-30.
3. Skarin AT, Canellos G, Rosenthal DS, et al. Moderate
dose methotrexate (m) combined with bleomycin (B),
adriamycin (A), cyclophosphamide (C), oncovin (O)
end dexamethasone (D), m-BACOD, in advanced dif-
fuse histiocytic lymphomas (DHL) [abstract]. Proc Am
Soc Clin Oncol 1983; 2:220.
4. Klimo P, Connors J. MACOP-B chemotherapy for the
treatment of diffuse large-cell lymphoma. Ann Int Med
1985;102:596-602.
5. Fisher RI, De Vita VT Jr, Hubbard SM, et al. Random-
ized trial of ProMACE-MOPP vs ProMACE-CytaBOM
in previously untreated, advanced diffuse aggressive
lymphomas [abstract]. Proc Am Soc Clin Oncol 1984;
3:242.
6. Coiffier B, Lepage E. Prognosis of aggressive lym-
phomas. A study of five prognostic models with
patients included in LNH-84 regimen. Blood 1989;
74:558-64.
7. Amadori S, Guglielmi C, Anselmo AP, et al. Treatment
of diffuse aggressive non-Hodgkin's lymphomas with
an intensive multi-drug regimen including high-dose
cytosine arabinoside (F-MACHOP). Semin Oncol
1985; 12 (Suppl 3):218-22.
8. Boyd DB, Coleman M, Papish SW, et al. COPBLAM
III: infusional combination chemotherapy for diffuse
large-cell lymphoma. J Clin Oncol 1988; 6:425-33.
9. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison
of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin's
lymphoma. N Engl J Med 1993; 328:1002-6.
10. Gordon LI, Harrington D, Anderson J, et al. Compar-
ison of a second-generation combination chemother-
apeutic regimen (m-BACOD) with a standard regimen
(CHOP) for advanced diffuse non-Hodgkin’s lym-
phoma. N Engl J Med 1992; 327:1342-9.
11. Cooper IA, Wolf MM, Robertson TI, et al. Random-
ized comparision of MACOP-B with CHOP in patients
with intermediate-grade non-Hodgkin’s lymphoma. J
Clin Oncol 1984; 12:769-78.
12. Montserrat E, Garcia-Conde J, Vinolas N, et al. CHOP
vs. ProMACE-CytaBOM in the treatment of aggres-
sive non-Hodgkin’ s lymphomas: long term results of
a multicenter randomized trial. Eur J Haematol 1996;
57:377-83.
13. Meerwaldt JH, Carde P, Somers R, et al. Persistent
improved results after adding vincristine and bleo-
mycin to a cyclophosphamide/hydroxorubicin/Vm-
26/prednisone combination (CHVmP) in stage III-IV
intermediate- and high-grade non-Hodgkin’s lym-
phoma. The EORTC Lymphoma Cooperative Group.
Ann Oncol 1997; 8 (Suppl 1):67-70.
14. Gianni AM, Bregni M, Siena S, et al. High-dose chemo-
therapy and autologous bone marrow transplantation
compared with MACOP-B in aggressive B-cell lym-
phoma. N Engl J Med 1997; 336:1290-7.
15. Silingardi V, Federico M, Cavanna L, et al. ProMECE-
CytaBOM vs MACOP-B in advanced aggressive non-
Hodgkin’s lymphoma: long term results of a multi-
center study of the Italian Lymphoma Study Group
(GISL). Leuk Lymphoma 1995; 17:313-20.
16. Chisesi T, Santini G, Capnist G, et al. ProMACE-
MOPP vs MACOP-B in high grade non-Hodgkin's lym-
phomas: a randomized study in a multicentre coop-
erative study group (NHLCSG). Leukemia 1991; 5
M. Federico et al.810
(Suppl 1):107-11.
17. Tura S, Zinzani PL, Mazza P, et al. F-MACHOP vs
MACOP-B in the treatment of high grade malignant
non-Hodgkin's lymphomas. Blood 1991; 78 (Sup-
pl):109a.
18. Miller TP, Dahlberg S, Weick JK, et al. Unfavorable
histologies of non-Hodgkin's lymphoma treated with
ProMACE-CytaBOM: a groupwide Southwest Oncol-
ogy Group Study. J Clin Oncol 1990; 8:1951-8.
19. Carotenuto M, Federico M, Avanzini P, et al. A multi-
center randomized trial of two different ProMACE-
CytaBOM derived protocols in aggressive non-Hodgk-
in’s lymphomas (NHL). A preliminary report. Leuk
Lymphoma 1992; 7:25-8.
20. Brugiatelli M, Federico M, Gobbi PG, et al. Epidox-
orubicin vs idarubicin containing regimens in inter-
mediate and high grade non-Hodgkin's lymphoma:
preliminary results of a multicentric randomized trial.
Haematologica 1993; 78:306-12.
21. Italian Multicentre Breast Study with Epirubicin. Phase
III randomized study of Fluorouracil, Epirubicin, and
Cyclophosphamide v Fluorouracil, Doxorubicin, and
Cyclophosphamide in advanced breast cancer: an Ital-
ian multicentre trial. J Clin Oncol 1988; 6: 976-82.
22. Case BC, Hayes DM, Gerber M, et al. Phase II study
of oral idarubicin in favourable histology non Hodgk-
in’s lymphoma. Cancer Res 1990; 50:6833-5.
23. Nie HH, Hadlai H, Jenkins JG, et al. SPSS (statistical
package for the social sciences). New York , McGraw-
Hill, 1979. 
24. The International Non-Hodgkin's Lymphoma Prog-
nostic Factors Project. A  predictive model for aggres-
sive non-Hodgkin's lymphoma. N Engl J Med 1993;
329:987-94.
25. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic
factors in aggressive malignant lymphomas: descrip-
tion and validation of a prognostic index that could
identify patients requiring a more intensive therapy. J
Clin Oncol 1991; 9:211-9.
26. Swan F Jr, Velasquez WS, Tucker S, et al. A new siero-
logic staging system for large-cell lymphomas based
on initial b2-microglobulin and lactate dehydroge-
nase levels. J Clin Oncol 1989; 7:1518-27.
27. Hryniuk W, Bush H. The importance of dose intensi-
ty in chemotherapy of metastatic breast cancer. J Clin
Oncol 1984; 2:1281-8.
28. Longo DL, De Vita VT Jr, Duffey PL, et al. Superiority
of  ProMACE-CytaBOM over ProMACE-MOPP in the
treatment of advanced diffuse aggressive lymphoma:
results of a prospective randomized trial. J Clin Oncol
1991; 9:25.
29. Rossi G, Mariano MR, Arcangeli G, et al. A phase II tri-
al of ProMACE-Cytabom in previously untreated non-
Hodgkin’s lymphoma of intermediate- or high-grade
histology. Hematol Oncol 1991; 9:147-55.
30. Bertini M, Freilone R, Botto B, et al. Idarubicin in
patients with diffuse large cell lymphomas: a ran-
domized trial comparing VACOP-B (A=Doxorubicin)
vs VICOP-B (I=Idarubicin). Haematologica 1997; 82:
309-13.
31. Zinzani PL, Martelli M, Storti S, et al. Pase III com-
parative trial using CHOP vs CIOP in the treatment of
advanced intermediate-grade non-Hodgkin’s lym-
phoma. Leuk Lymphoma 1995;19:329-35.
32. Cassi E, Butti C, Baldini L, et al. A cooperative study
on ProMACE-CytaBOM in aggressive non-Hodgkin’s
lymphomas. Leuk Lymphoma 1994; 13:111-8.
33. Somers R, Card P, Thomas J, et al. Phase III study
comparing CHVmP-VB and ProMACE-MOPP in
patients with stage II, III and IV, intermediate- and
high-grade lymphoma. Ann Oncol 1994; 5 (Suppl 2):
85-9.
34. Bezwoda W, Rastogi RB, Valla AE, et al. Long term
results of a multicentre randomised, comparative
phase III trial of CHOP versus CNOP regimens in
patients with intermediate and high-grade non
Hodgkin’s lymphomas. Eur J Cancer 1995; 31: 903-
11.
35. Baldini L, Colombi M, Guffanti A, et al. A pilot study
on the use of the ProMACE-CytaBOM regimen as a
first line treatment of advanced follicular non Hodgk-
in’s lymphoma. Cancer 1997; 79:1234-40.
36. Longo G, Federico M, Pieresca C, et al. Anaplastic
large cell lymphoma. Analysis of 35 cases followed at
GISL centers. Eur J Cancer 1995; 31:1763-7.
37. Longo DL, Duffey PL. Management of aggressive his-
tology lymphoma: an approach based on data from
the National Cancer Institute. Ann Hematol Oncol
1993; 1:19-28.
38. Kwak LW, Halpern Y, Olshen RA, et al. Prognostic sig-
nigficance of actual dose intensity in diffuse large cell
lymphoma: results of a tree-structured survival analy-
sis. J Clin Oncol  1990; 5:756-65.
39. Epelbaum R, Faraggi D, Ben-Aire Y, et al. Survival of
diffuse large cell lymphoma. A multivariate analysis
including dose intensity variables. Cancer 1990;
66:1124-9.
40. Meyer RM, Quirt IC, Skillings JR, et al. Escalated as
compared with standard doses of doxorubicin in
BACOP therapy for patients with non-Hodgkin's lym-
phoma. New Engl J Med 1993; 329:1770-6.
41. Meyer RM, Hryniuk WM, Goodyear MDE. The role of
dose intensity in determining outcome in intermedi-
ate-grade non-Hodgkin’s lymphoma. J Clin Oncol
1991; 9:339-47.
42. Gordon LI, Andersen J, Habermann TM, et al. Phase
I trial of dose escalation with growth factor support in
patients with previously untreated diffuse aggressive
lymphomas: determination of the maximum-tolerat-
ed dose of ProMACE-CytaBOM. J Clin Oncol 1996;
14: 1275-81.
43. Shipp MA, Neuberg D, Janicek M, et al. High dose
CHOP as initial therapy for patients with poor-prog-
nosis aggressive non-Hodgkin’s lymphoma: a dose-
finding pilot study. J Clin Oncol 1995; 13:2916-23.
44. Tanosaki R, Shinichiro O, Noriko A, et al. Dose esca-
lation of biweekly cyclophosphamide, doxorubicin,
vincristine, and prednisolone using recombinant
human granulocyte colony-stimulating factor in non-
Hodgkin’s lymphoma. Cancer 1994; 74: 1939-44.
45. Bergmann l, Karakas T, Lautenschläger G, et al. Vin-
cristine, doxorubicin, cyclophosphamide, prednisone
and etoposide (VACPE) in high-grade non-Hodgkin’s
lymphoma - a multicenter phase II study. Oncology
1995; 6:1019-24.
46. Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified
and high-dose chemotherapy with granulocyte colony-
stimulating factor and autologous stem cell trans-
plantation support as first line therapy in high risk
large cell lymphoma. J Clin Oncol 1997; 15:491-8.
ProMACE-Cytabom different regimens in aggressive NHL 811
